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Carmen J Marsit3 , Heather H Nelson4 , John K Wiencke5 and Karl T Kelsey2,6

Abstract
Background: There has been a long-standing need in biomedical research for a method that quantiﬁes the normally
mixed composition of leukocytes beyond what is possible by simple histological or ﬂow cytometric assessments. The
latter is restricted by the labile nature of protein epitopes, requirements for cell processing, and timely cell analysis. In
a diverse array of diseases and following numerous immune-toxic exposures, leukocyte composition will critically
inform the underlying immuno-biology to most chronic medical conditions. Emerging research demonstrates that
DNA methylation is responsible for cellular diﬀerentiation, and when measured in whole peripheral blood, serves to
distinguish cancer cases from controls.
Results: Here we present a method, similar to regression calibration, for inferring changes in the distribution of white
blood cells between diﬀerent subpopulations (e.g. cases and controls) using DNA methylation signatures, in
combination with a previously obtained external validation set consisting of signatures from puriﬁed leukocyte
samples. We validate the fundamental idea in a cell mixture reconstruction experiment, then demonstrate our
method on DNA methylation data sets from several studies, including data from a Head and Neck Squamous Cell
Carcinoma (HNSCC) study and an ovarian cancer study. Our method produces results consistent with prior biological
ﬁndings, thereby validating the approach.
Conclusions: Our method, in combination with an appropriate external validation set, promises new opportunities
for large-scale immunological studies of both disease states and noxious exposures.
Background
The biology of the development of any multisystem life
form is fundamentally grounded in systematic cellular
diﬀerentiation. This is essentially deﬁned by lineage commitment of cells whose origin can be traced to a pluripotent progenitor and is marked by mitotically heritable
epigenetic changes that reﬂect complex transcriptional
programming of gene expression within the individual
cell [1-3]. One such epigenetic mark is DNA methylation, which is tightly associated with alterations in the
nucleosome DNA scaﬀold (and hence chromatin) that is
responsible for coordination of gene expression in individual cells [1-3]. It is now appreciated that diﬀerentially
methylated DNA regions (DMRs) distinguish cell lineages
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with high sensitivity and speciﬁcity [4] and considerable
research is now underway to delineate precise DMRs that
deﬁne and specify a particular cell lineage. The most
developed understanding of epigenetic markers of lineage
commitment to date is perhaps that of immune cell subclasses deﬁned by populations of distinct circulating blood
cells [5,6].
Pluripotent hematopoietic stem cells residing in the
bone marrow continually give rise to the entire hierarchy
of blood cell subclasses through a developmental process
known as hematopoiesis. Leukocytes, commonly called
white blood cells, are critical in the host response to
pathogens and foreign antigens and are divided into two
compartments, the myeloid lineage and lymphoid lineage
(also called lymphocytes). The composition of leukocyte
populations is well known to reﬂect disease states and toxicant exposures and can be altered by signaling cascades
that prompt migration of whole classes of cells into or out
of tissues. Several DMRs that serve as reliable biomarkers
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of individual human white blood cell types have already
been identiﬁed [5,6]. Individual assays identifying cellspeciﬁc DMRs have proven useful for quantifying individual cell types in human tissues and peripheral blood.
However, these assays are limited to detecting the relative proportion of one individual cell type compared with
all others. On the other hand, simultaneous quantiﬁcation
of ﬂuctuation in overall lymphocyte population composition can be accomplished only by using methods based
on ﬂow cytometry, which require large volumes of fresh
blood and involve laborious antibody tagging. Hence, an
approach that allows for the simultaneous quantiﬁcation
of the entire distribution of cell types, using an array
of biomarkers based on generally available technology,
would be considerably more informative, especially in
studies of human disease and exposures.
In some instances, it is generally the overall balance of leukocyte subclasses in circulation or tissue that
most prominently inﬂuences pathogenesis. For example,
although incipient cancer cells are recognized and eliminated by cytotoxic T-cells (CTLs) and natural killer (NK)
cells, tumorigenesis is also promoted by certain other
inﬂammatory cells, including B-lymphocytes, mast cells,
neutrophils, regulatory T-cells (Tregs), and numerous
others. All of these cells have been shown to promote
angiogenesis, tumor cell proliferation, tissue invasion and
metastasis [7,8]. Likewise, while higher levels of NK cells
and CTLs circulating in the blood and residing in adipose
tissues are associated with lower incidence of metabolic
diseases such as type II diabetes [9], higher levels of
M1 macrophages in adipose tissue can induce inﬂammation and insulin resistance [10]. These examples illustrate
incredible potential for methods of quantifying the composition of lymphocyte populations to critically inform
the underlying immuno-biology of disease states as well as
the immune response to almost all chronic medical conditions. In addition, they oﬀer great potential for predicting
therapeutic outcomes [11].
Here we employ the concept of DMRs as markers of
immune cell identity using a high density methylation
platform, and propose a set of analytical tools for estimating the proportions of immune cells in unfractionated
whole blood that does not require fresh cells. The backbone of the approach is the DNA methylation signature
of each of the principal immune components of whole
blood (B cells, granulocytes, monocytes, NK cells, and T
cells subsets). We essentially seek a form of regression calibration, where we consider a methylation signature to be
a high-dimensional multivariate surrogate for the distribution of white blood cells. In turn, this distribution is
of interest for predicting or modeling disease states. As a
surrogate, the DNA methylation signature is assumed to
be a highly correlated, yet imperfect, measure of leukocyte distribution, and thus ﬁts into the framework of
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measurement error models, where the use of a noisy surrogate marker to investigate an association with a disease
outcome of interest results in biased estimates, unless
internal or external validation data can be obtained to
“calibrate” the model and correct the bias [12]. However,
in this case, the problem is complicated by the extremely
high dimension of the surrogate, so we propose an alternative to the traditional regression-calibration procedure
that circumvents these complications but still allows us to
extract the desired biological information.
We note that since we began this work, a small number
of authors have published similar deconvolution algorithms using gene expression data [13-15]. The techniques
are similar to the quadratic programming method we
describe below in Methods for deconvolving a single
sample, but none comprehensively addresses statistical
properties or employs data from DNA methylation.

Methods
In this section we describe our proposed statistical methods, the data sets used to demonstrate their utility, and
ﬁnally the design of simulation studies we have conducted to investigate statistical properties of our proposed
algorithms.
Statistical methods

Let Y0h be an m × 1 vector of methylation assay values,
e.g. average beta values from an Inﬁnium bead-array product corresponding to a puriﬁed blood sample consisting
of a homogenous cellular population (e.g. monocytes or
granulocytes), with the qualitative characterization of cell
type (among d0 such types) indicated by a d0 × 1 covariate vector wh . Here, h ∈ {1, . . . , n0 }, where n0 is the
number of specimens and the m individual values correspond to CpG sites on a DNA methylation microarray,
possibly pre-selected to correspond to putative DMRs
for distinguishing diﬀerent cellular types. Correspondingly, let Y1i be an m × 1 vector of methylation assay
values for the same CpG sites (in the same order) as
Y0h , but corresponding to a heterogeneous mixture of
cells (e.g. peripheral whole blood) from a human subject. Here, i ∈ {1, . . . , n1 }, n1 is the number of target
specimens, and z1i is a d1 × 1 covariate vector representing phenotypes or exposures corresponding to the
subject, e.g. d1 = 2 for a simple case/control study
without confounders. Our goal is to understand the associations between Y1i and z1i in terms of associations
between Y0h and w0h , i.e. to infer changes in mixtures of cell types associated with phenotypes or exposures, using DNA methylation as a surrogate measure of
cell mixture. Thus, we have two data sets, S0 = {(Y01 ,
w1 ), . . . , (Y0n0 , wn0 )}, the set of data from “puriﬁed” cell
samples eﬀectively representing external validation or
gold-standard data, and S1 = {(Y11 , z1 ), . . . , (Y1n1 , zn1 )},

Houseman et al. BMC Bioinformatics 2012, 13:86
http://www.biomedcentral.com/1471-2105/13/86

Page 3 of 16

representing surrogate data collected from a target population. To this end, we posit the following linear models:
Y0h = B0 w0h + e0h

(1)

Y1i = B1 z1i + e1i ,

where B0 and B1 are, respectively, m × d0 and m × d1
matrices and e0 and e1 are error vectors. For simplicity
we assume a one-way ANOVA parameterization for w,
though in the Additional ﬁle 1 we describe slight generalizations to account for design complications met in
practice. We also assume a reasonable regression parameterization for z, including an intercept, and for convenience, denote the ﬁrst column of B0 as μ1 , the m × 1
intercept. The error vectors e0 and e1 may reﬂect independence among arrays h and i, or else may have more complex random eﬀects structure accounting for technical
eﬀects or biological replication; however, their substructures are incidental to this analysis, with the exception
of the ﬁne details of the bootstrap procedure proposed
below.
To implement a surrogacy relation, we propose the
following linking regression model:
B1 = 1m γ0T + B0  + U,

(2)

where  is a d0 × d1 matrix that summarizes associations between the rows of B0j and B1i and U is a
matrix of errors. Substituting equation (2) into (1), writing
B0 = (b01 , . . . , b0d0 ) explicitly in terms of its columns and
writing  T = (γ1 , . . . , γd0 ), it follows that
Y1i =

d0


b0l (γlT z1i ) + (1m γ0T + U)z1i + e1i .

(3)

l=0

To impart a biological interpretation, we assume that the
DNA assayed in S1 arises as a mixture of DNA from
cell types proﬁled in S0 , with mixture coeﬃcients whose
},
population averages, conditional on z, are {ω1(z) , . . . , ωd(z)
0
so that
E(Y1i |z1i = z) = ξ (z) +

d0


(z)

b0l ωl ,

(4)

l=1

where the m × 1 vector ξ (z) represents cell types excluded
from consideration among the puriﬁed samples in S0 , or
else non-cell-speciﬁc methylation, including alterations at
the molecular level in the maintanence of DNA methylation patterns themselves (possibly exposure related, age,
or disease related). It follows from (3) and (4) that the mixture coeﬃcients are recoverable from , ωl(z) = γlT z1i ,
provided ξ (z) is orthogonal to the column space of B0 .
As we discuss in detail in the Additional ﬁle 1, bias
can arise if diﬀerences in ξ (z) between distinct values

of z have nonzero projection onto the column space of
B0 , although the magnitude of anticipated biases can be
assessed through sensitivity analysis.
It is possible to assign interpretations to the components
of variation in (3). Let SSo represents overall variability in
 1
Y1i − μ̄1 2 , where μ̄1 = E(Y1i ). From
Y1i , i.e. SSo = ni=1
multivariate probability theory it is straightforward to
 1
e1i 2 ,
show that SSo = SSe +SSv +SSu , where SSe = ni=1
n1
T
T T
SSv =
i=1 (z1i − z̄1 )  B0 B0 (z1i − z̄1 ), and SSu =
n1
T
T
T
T
i=1 {(z1i − z̄1 ) U U(z1i − z̄1 ) + m(z1i − z̄1 ) γ0 γ0 (z1i −
z̄1 )}. SSe measures variation unexplained by the covariates z1i , presumed to represent a combination of technical
noise and unsystematic biological heterogeneity. SSv measures variability explained by mixtures of proﬁles in the
set S0 , while SSu measures variability in systematic biological heterogeneity that nevertheless remains unexplained
by mixtures of proﬁles in S0 , presumably due to some
process other than diﬀerences in mixtures of cell types.
Thus we propose two partial coeﬃcient of determination
measures: R21,0 = SSv /SSo , which represents the proportion of total variation in S1 explained by S0 , and R21,1 =
SSv /(SSo − SSe ), which represents the proportion of systematic variation in S1 explained by S0 . Note that R21,1 is
poorly deﬁned when SSo ≈ SSe .
Estimation procedes by applying an appropriate linear
model, e.g. ordinary least squares, linear mixed eﬀects
models [16], limma [17], or surrogate variable analysis
B1 . Estimates of γ0
[18,19], to obtain estimates 
B0 and 
and  are then obtained by projecting 
B1 onto the column space of B̃0 = (1m , B0 ), as described in detail in the
Additional ﬁle 1. Standard errors can be obtained in one
of three ways. The simplest estimator, SE0 , is the “naive”
estimator from simple least-squares theory, ignoring the
B1 are estimates, i.e. potentially variable.
fact that 
B0 and 
To account for variation in estimating 
B1 , a simple alternative is to use a nonparametric bootstrap procedure. For
each bootstrap iteration t, we sample with replacement
from S1 (or sample errors in a manner consistent with a
(t)
hierarchical experimental design) to obtain S1 , produc(t)
ing bootstrap estimates 
B1 from which “single-bootstrap”
standard errors SE1 are computed. Finally, it is possible
to account for variation in estimating B0 by also bootstrapping S0 ; because of potentially small sample sizes
n0 , we propose using a parametric bootstrap. A“doublebootstrap” standard error estimator, SE2 , is computed
from these two sets of bootstraps. The double-bootstrap
has the additional beneﬁt over the single-bootstrap, in that
it can be used to assess bias due to measurement error
(variability) in 
B0 . Estimation details are provided in the
Additional ﬁle 1, as are the results of simulation studies.
Beyond bias due to measurement error, which is easily
corrected using the double-bootstrap procedure, there are
additional sources of potential bias. For example, consider
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a univariate z1i representing case/control status, where
δ ≡ ξ (1) − ξ (0) = B0 α for some d0 × 1 vector α  = 0; i.e.
δ is the mean diﬀerence in DNA methylation between a
case and control, contributed by cell mixtures that remain
uncharacterized or non-cell-speciﬁc methylation. In such
a situation, there will be a bias equal to α in estimating
the mixture diﬀerences. The Additional ﬁle 1 provides a
detailed analysis of such biases, and proposes a sensitivity
analysis procedure for assessing the magnitude of possible
bias in a given data set.
While the focus of this paper is analysis of population
data, it is possible to use S0 to predict distribution of
leukocytes in a single sample having DNA methylation
proﬁle Y∗ . Equating the intercept term of B1 in (1) with Y∗
and applying (2), we obtain mixing proportion estimates
−1 T ∗
 ∗ = (B̃T
0 B̃0 ) B̃0 Y . Estimates can be further reﬁned
with the use of quadratic programming techniques [20],
restricting the components of  ∗ , γl∗ ≥ 0, in minimizing Y∗ − B̃0  ∗ 2 with respect to  ∗ . Such individual
projections of methylation proﬁles on the column space
spanned by S0 facilitate the application of the fundamental ideas proposed above to individual, clinically-based
diagnostic procedures. Note, however, that DNA methylation arrays are typically focused on the comparison
of methylated to unmethylated CpG dinucleotides, not
quantifying actual amounts of DNA. Therefore, information on cell mixtures from DNA methylation is limited
to distributions, not actual counts, as one might obtain
from ﬂow cytometry. Finally, we remark that it is possible
to model z1i directly as a function of mixture coeﬃcients
 ∗ obtained individually via the constraint γl∗ ≥ 0, but
the inferential implications are less clear, and we view the
proposed approach for populations as more statistically
robust.
Implementation

We describe several examples using existing methylation data sets as benchmarks for validating the proposed
method, in order to demonstrate its clinical or epidemiological utility. First we describe the validation data set S0
used in all examples. Next we describe a laboratory reconstruction experiment, which validates our fundamental
proposition that DNA methylation retains substantial
information about cell mixtures. Finally we describe the
results of applying our methodology to several diﬀerent
target data sets S1 . For the head and neck cancer and
ovarian cancer data sets, from which bead chip data were
available, a linear mixed eﬀects model with a random
intercept for bead chip was used to estimate the corresponding row of B1 . For the remaining data sets, no
bead chip data were available; consequently, ordinary least
squares was used. 250 bootstrap iterations were used for
each example and each of the two bootstrap methods of
standard error estimation.
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Validation data

All data analyses involve DNA methylation data obtained
by the Inﬁnium HumanMethylation27 Beadchip Microarrays from Illumina, Inc. (San Diego, CA). We used a
subset of m = 100 CpG sites on the array, selected as
described below. In all of our examples, S0 consisted of
46 white blood cell samples, de-identiﬁed specimens that
were not subject to human subjects review by an institutional review board (IRB). The sorted, normal, human,
peripheral blood leukocyte subtypes were purchased from
AllCells , LLC (Emeryville, CA) and were isolated from
whole blood using a combination of negative and positive
selection with highly speciﬁc cell surface antibodies conjugated to magnetic beads; materials and protocols were
obtained from Miltenyi Biotec, Inc. (Auburn, CA). These
46 samples are summarized in Table 1 and depicted by
the clustering heatmap in Figure 1. Note that T lymphocytes that express CD4 or CD8 constitute over 95% of
the T cell class, and that the pan-T cell type was further reﬁned to CD4+, CD8+, and “other” Pan-T cells
subtypes. In summary, the covariate vector wh consisted
of indicators for ﬁve cell types and another two indicators for CD4+ and CD8+ T cell subtypes. A generalization of the one-way ANOVA parameterization assumed
above for wh , described in the Additional ﬁle 1, was
necessary to account for the ambiguous status of some
Pan-T cells. For each CpG site, a linear mixed eﬀects
model with a random intercept for bead chip was used
to estimate B0 ; 27 additional whole blood control samples
(replicates from the same individual) were used to assist
in estimating chip eﬀects, since otherwise the data set
would have been suﬃciently sparse to risk confounding
between cell type and chip. These “array controls” were
indicated with an additional term in w0h . For each CpG
site, a linear mixed eﬀects model with a random intercept for bead chip was used to estimate the corresponding row of B0 and B1 . From S0 , F statistics (described
in the Additional ﬁle 1) were computed and used to

Table 1 Sorted white blood cells in S0
Short name

Description

B cells

CD19+ B-lymphocytes

Number
6

Granulocytes

CD15+ granulocytes

8

Monocytes

CD14+ monocytes

5

NK

CD56+ Natural Killer (NK) cells

11

1,2

CD3+CD4+ T-lymphocytes

8

T cells (CD8+)1,3

CD3+CD8+ T-lymphocytes

2

CD3+CD56+ natural killer

1

CD3+ T-lymphocytes

5

T cells (CD4+)

T cells (NKT)

1

T cells (other)1
1

Considered as a member of the “pan-T-cell” group.
Pan-T-cell further reﬁned as also belonging to the “CD4+” group.
3
Pan-T-cell further reﬁned as also belonging to the “CD8+” group.
2
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Figure 1 Clustering heatmap for external validation white blood cell data (S0 ). Yellow = unmethylated (Yhj = 0), black = partially methylated
(Yhj = 0.5), blue = methylated (Yhj = 1).

order each of the 26,486 autosomal CpGs by decreasing level of informativeness with respect to blood cell
types. As described in the Additional ﬁle 1, we determined that maximum informativeness was provided by
the top m = 100 − 300 CpG sites, with m > 300 reﬂecting diminishing returns from adding additional CpGs.
Therefore, we chose a moderately low value in this range,
m = 100, consistent with the size of a small custom
microarray chip.
Cell mixture experiment

Proof of the utility of the proposed methods in predicting leukocyte distributions for individual samples requires
extensive, detailed reconstruction experiments beyond
the scope of the present paper. However, to provide evidence that such experiments are worthwhile and show
promise of positive results, we conducted a simple experiment involving six known mixtures of monocytes and
B cells and six known mixtures of granulocytes and T

cells. The results of this experiment are described below
in Results.
Head and neck cancer

Our ﬁrst target data set S1 consisted of arrays applied to
whole blood specimens collected in a random subset of
individuals involved in an ongoing population-based casecontrol study [21] of head and neck cancer (HNSCC):
92 cases and 92 age and sex matched controls. The
study was approved by Brown University IRB, protocol
#0707992334. Blood was drawn at enrollment (prior to
treatment in 85% of the cases). Mean age among the subjects arrayed in this study was 60 years, and there were
56 females and 128 males, consistent with the higher incidence of the disease in men. Thus, the covariate vector z
consisted of an indicator for case/control status, an indiator for male sex, and age (in decades) centered at the
mean. The clustering heatmap in Figure 2 depicts the raw
DNA methylation data in S1 .
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Figure 2 Clustering

 heatmap for target HNSCC data (S1 ). Yellow = unmethylated Yij = 0 , black = partially methylated Yij = 0.5 , blue =
methylated Yij = 1 . The annotation track above the heatmap indicates case-control status (orange = case, purple = control).

Ovarian cancer

We next applied our method to an ovarian cancer
data set [22]. DNA methylation data for blood samples
are available from Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/, Accession number
GSE19711). We used only those cases having blood
drawn pre-treatment. After removing 4 arrays with a
preponderance of missing values, the data set consisted
of 272 controls and 129 cases having blood drawn prior
to treatment. A clustering heatmap displaying the DNA
methylation data appears in the Additional ﬁle 1. In this
analysis, z consisted of case-control status, age (categorized in 5-year increments), and 2 bisulﬁte conversion
eﬃciency measures.
Down syndrome

We also applied our method to a trisomy 21 (Down syndrome) data set [23] consisting of 29 total peripheral blood
leukocyte samples from Down syndrome cases and 21

controls, as well as 6 T cell samples from cases and 4
T cell samples from controls (GEO Accession number
GSE25395). Because of the potential for bias induced by
copy number ampliﬁcation, we excluded 4 CpG sites on
Chromosome 21, resulting in m = 96 CpG sites used
for analysis. A clustering heatmap displaying the DNA
methylation data appears in the Additional ﬁle 1. In one
analysis, we compared cases and controls using the total
leukocyte samples only, and in another we compared total
leukocytes to T cells, pooling cases and controls. The
Additional ﬁle 1 presents coeﬃcient estimates.
Obesity in African Americans

Finally, we applied our method to an obesity data set
[24] consisting of 7 lean African-Americans and 7 Obese
African-Americans (GEO Accession number GSE25301).
A clustering heatmap displaying the DNA methylation
data appears in the Additional ﬁle 1. In this analysis, z
consisted of obesity status.
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Additional analyses

If the subject population for which z = 0 is suﬃciently
homogeneous with respect to blood cell distribution to
admit sensible characterization of that distribution, then
it is possible to recover estimates from 
. The Additional
ﬁle 1 reports the results of such an analysis applied to the
HNSCC case/control data set. Finally, we conducted an
additional analysis where we took S0 to consist of only
samples with pure CD4+ or CD8+ cells and S1 to consist
only of samples having the less puriﬁed T-lymphocytes.
For such S1 , there were no covariates, so z consisted only
of an intercept.
Simulations

We conducted extensive simulation studies in order
to verify the ﬁnite-sample statistical properties of our
proposed methodology. Simulation parameters were
obtained from the HNSCC data set, and most simulations
assumed no sources of biological bias (DNA methylation
changes arising from processes not mediated by the proﬁled leukocytes, including shifts in distribution within cell
types not proﬁled). In every simulation, we speciﬁed S0
to consist of 5 B-cell samples, 10 granulocyte samples,
5 monocyte samples, 15 NK samples, 5 general “Pan-T”
T-cell samples, 8 speciﬁc CD4+ T cell samples, and 2 speciﬁc CD8+ T cell samples. Estimates from the external
validation set S0 , described above, were used for mean
methylation proﬁles among WBC types, using the m =
100 most informative CpG sites.
We speciﬁed n1 /2 cases and n0 /2 controls, n0 ∈
{100, 200, 500}. Among the controls, methylation proﬁles
were generated by a white blood cell population of 7% Bcells, 62% granulocytes, 6% monocytes, 2% NK cells, and
13% were T-cells, of which 65% were CD4+ cells and 35%
were CD8+ cells, and the remaining 5% were unspeciﬁed
(and assumed to have mean methylation equal to that of
the unsorted T-lymphocytes). Among cases, we speciﬁed
one of the following scenarios: a 4% reduction in CD4+
cells, a 2% reduction in CD8+ cells, and an 8% increase in
granulocytes (alternative with changes in both CD4+ and
CD8+, “Strong Alternative I”); a 6% reduction in CD4+
cells, and an 8% increase in granulocytes (alternative with
changes in CD4+ but not CD8+, “Strong Alternative II”);
a weaker alternative with half the eﬀects of Strong Alternative I (“Mixed Alternative” elaborated upon below); and
two null scenarios with no changes in cell population,
each with a diﬀerent assumption about δ. Note that these
changes reﬂect absolute changes in percentage points, not
relative changes. Note also that these values were actually
used to generate Dirichlet-distributed mixture weights for
each simulated subject, with Dirichlet parameters equal
to a precision parameter (100 corresponding to “precise”
and 10 corresponding to“noisy”) times the mean weight
(0)
described above. Residual eﬀects ξi for controls were
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set equal to 0.1 times estimated intercept estimate 
μ1
obtained from the HNSCC data set, while residual eﬀects
(1)
μ1 plus
ξi for cases were set equal to 0.08 or 0.09 times 
 corresponding to case.
multiples 10θ of the column of U
The constants of proportionality 0.1, 0.08, and 0.09 were
chosen to correspond to assumed contributions of ξ to an
overall methylation signature presumed to be dominated
by proﬁled populations of white blood cells in speciﬁed
proportions, with 0.08 used for the strong alternatives and
0.09 used for the Mixed Alternative. The constant 10 was
used to amplify the scale of δ so that its eﬀect could be
 was orthogonal to the
detected in simulation; note that U
white blood cell proﬁles, by construction. The multiplier
θ = 0 was used for strong alternatives, and the “Strong
Null” case (i.e. no methylation diﬀerences between cases
and controls) while θ = 0.5 was used for the Mixed
Alternative, and θ = 1 was used for the “Mixed Null”
with case/control diﬀerences not mediated by cellular
population diﬀerences. A simple normal error structure
for e0h and e0i was speciﬁed, with no chip eﬀects, but with
variance equal to the sum of chip and residual variance
estimated (individually for each CpG) for the HNSCC
data. For each simulation, 50 bootstraps were used to
estimate standard errors. 1000 simulations were run for
each scenario.

Results
In this section we report the results of the data analyses
described above in Implementation, as well as the results
of our simulation experiments.
Cell mixture experiment

As Figure 3 suggests, accuracy is within 10%, and often
less than 5%, with the largest errors occuring for granulocytes, as shown in Table 2. Note that the sum of the
individual observed predictions for each individual proﬁle ranged from 98.9% to 102.7% (data not shown), even
though the constraints of the projection do not explicitly
constrain the sum to 100%; this provides additional evidence that the DNA methylation proﬁle captures a great
deal of information about cell mixtures.
Head and neck cancer

Table 3 presents coeﬃcient estimates 
 for case status,
double-bootstrap bias estimates (estimates of bias arising from measurement error), as well as naive, singlebootstrap, and double-bootstrap standard error estimates.
Each of these quantities is measured in percentage
points (%). Estimates of bias arising from measurement
error (i.e. substituting estimated quantities for known
ones in a two-stage statistical procedure) were almost
always less than half a percentage point, and for significant coeﬃcient estimates, always towards the null. The
proportion of CD4+ T-lymphocytes decreased in cases
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Figure 3 Results of cell mixture reconstruction experiments validating prediction of individual proﬁles. Expected and observed
percentages of each cell type are shown by color (red=100, white=0) and text. Median root-mean-square-error over 12 samples had a median value
of 8.2%, ranging from 5.4% to 11.6%.

compared with controls, with a bias-corrected estimate of
−10.4 percentage points and approximate 95% conﬁdence
interval (−13.1%, −3.3%); the proportion of NK cells
decreased, with a bias-corrected estimate of -1.5 percentage points and 95% conﬁdence interval (−2.2%, −0.75%);
and the proportion of granulocytes increased, with a biascorrected estimate of 7.6 percentage points and 95% conﬁdence interval (4.2%, 10.9%). There was also somewhat
weaker evidence of an increase in CD8+ T-lymphocytes,
with an estimate of 4.5 percentage points and 95% conﬁdence interval (2.0%, 7.0%). As reported in the complete set of results appearing in the Additional ﬁle 1,
the proportion of CD4+ T-lymphocytes decreased by
3.3 percentage points (−4.4%, −2.2%) per decade of age,
while CD8+ T-lymphocytes increased by 2.0 percentage
point (1.0%, 3.0%) per decade. All other coeﬃcients were
insigniﬁcant.
For this analysis, R21,0 was estimated at 14.2%,
while R21,1 was estimated at 93.9%. Thus, a small but
non-negligible proportion of total variation (systematic
variation + unexplained biological heterogeneity + technical noise) appeared to be driven by changes in cell
population between cases and controls and as a result of
aging. Note that SSe comprised 85% of total variation, so

a substantial portion of variability in DNA methylation
appeared to remain unexplained (presumably due, in
large part, to technical noise). However, almost all of the
systematic variation appeared to be explained by changes
in cell population.
These results were consistent with previous studies, as
HNSCC patients are known to display an absolute and relative increase in myeloid derived granulocytes [25] while
also displaying an alteration in lymphoid T-cell homeostasis that leads to decreases in CD4+ T-cells [26,27]. In addition, the proportion of Treg cells (a subclass of CD4+ T
cells) is known to decrease from infancy to adulthood [28].
The bias estimates obtained from the double-bootstrap
procedure allow the correction of bias arising from

Table 2 Summary statistics for errors in cell mixture
reconstruction results*
B cell

Granulocyte

Monocyte

NK

T cell

minimum

0.0

0.3

0.0

0.0

0.0

median

0.1

6.5

1.1

2.1

0.3

maximum

5.5

10.0

4.1

6.4

5.3

*

|Observed% − Expected%|.
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Table 3 Estimates for HNSCC analysis (case vs. control)
Est

Bias2

SE0

SE1

SE2

P-value

(Intercept, γ0 )

−0.62

−0.02

0.41

0.52

0.52

0.23

B Cell

−0.45

0.04

0.30

0.77

0.76

0.55

7.51

−0.07

0.50

1.73

1.71

<0.0001

Granulocyte
Monocyte

0.49

0.10

0.50

0.47

0.48

0.31

NK

−1.43

0.06

0.56

0.37

0.38

0.00017

T Cell (cd4+)

−9.08

1.32

1.95

1.15

1.39

<0.0001

T Cell (cd8+)

3.06

−1.46

1.96

0.98

1.27

0.016

Est = Regression coeﬃcient estimate (× 100%).
Bias2 = Double-bootstrap bias estimate (× 100%).
SE0 = Naive standard error (× 100%).
SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
P-values were computed using SE2 .

measurement error. However, there is no statistical procedure for correcting the other possible sources of bias,
those arising from changes in distribution among unproﬁled cell types as well as non-immune-mediated methylation diﬀerences. The Additional ﬁle 1 presents a detailed
sensitivity analysis, from which we show that the magnitude of the resulting bias is likely to be small, less than a
percentage point.
Ovarian cancer

Table 4 presents results for case-control status, with
the remaining results appearing in the Additional ﬁle 1.
R21,0 was estimated at 17.8%, while R21,1 was estimated
at 86.1%.
Compared with controls, cases showed signiﬁcant
increases in granulocytes and signiﬁcant decreases in B
cells, NK cells, and CD4+ T cells. Cases also showed
marginally signiﬁcant increases in monocytes. These
results are consistent with previous literature, where

Table 4 Estimates for ovarian cancer analysis (case vs.
control)
SE0

SE2

P-value

Down syndrome

The only signiﬁcant diﬀerence between cases and controls
was in B cell distribution, with bias-corrected estimated
decrease of 4.8%, 95% conﬁdence interval (−6.2%, −3.5%).
This result is consistent with known immune characteristics of Down Syndrome, including deﬁciencies in both B
and T cells [32,33]. However, in the comparison between
total leukocytes and T cells, all coeﬃcients except B Cell
and NK were highly signiﬁcant, in directions consistent
with comparison of a sample of puriﬁed T cells to a generic
whole blood sample. In fact, an estimate of the cellular composition of the T cell samples can be obtained
by a simple linear transformation of  estimates (adding
intercept terms with the T cell coeﬃcients); this operation produces values that are not signiﬁcantly distinct
from zero for all cell types except CD4+ and CD8+, whose
bias-corrected estimates were, respectively, 75.9%, 95%
conﬁdence interval (67%, 85%) and 8.6%, 95% conﬁdence
interval (0%, 17%), consistent with the known distribution
of these T cells. For the analysis of case vs. control within
total leukocytes, R21,0 was estimated at 4.5%, while R21,1
was estimated at 67.6%. For the analysis of total leukocyte
vs. T cell with pooled cases and controls, R21,0 was estimated at 81.4%, while R21,1 was estimated at 98.9%. The
latter set of coeﬃcients of determination indicate that a
substantial portion of variation is explained by composition of leukocytes, which is the expected result for such an
analysis.

Est

Bias2

(Intercept, γ0 )

−0.05

−0.05

0.41

0.19

0.20

0.81

B Cell

−1.36

0.02

0.29

0.22

0.23

<0.0001

Granulocyte

8.97

−0.04

0.49

1.02

1.00

<0.0001

Monocyte

0.55

0.06

0.49

0.29

0.30

0.066

NK

−2.09

0.01

0.55

0.31

0.34

<0.0001

Obesity in African Americans

T Cell (cd4+)

−5.64

0.18

1.93

1.06

1.34

<0.0001

T Cell (cd8+)

−0.35

−0.17

1.93

0.95

1.19

0.77

Obese subjects had an estimated increase of 12 percentage points in granulocytes, bias-corrected 95% conﬁdence interval (3.4%, 20%) and an estimated decrease
of 4 percentage points in NK cells, bias-corrected 95%
conﬁdence interval (−7.7%, −0.9%). No signiﬁcant diﬀerences were found for other blood cell types. Note that
the speciﬁc immunological diﬀerences estimated by the

Est = Regression coeﬃcient estimate (× 100%).
Bias2 = Double-bootstrap bias estimate (× 100%).
SE0 = Naive standard error (× 100%).
SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
P-values were computed using SE2 .

SE1

it has been demonstrated that ovarian cancer patients
experience decreases in B and T lymphocytes [29-31],
increases in monocytes [29,30] and (somewhat equivocally) increases in eosinophil granulocytes [30]. Additionally, there were signiﬁcant systematic decreases in CD4+
T cells with increasing age, with a gradient consistent
in direction and somewhat consistent in magnitude with
the corresponding eﬀect found in the HNSCC data set.
Though most of the CD8+ T cell coeﬃcients for age were
not signiﬁcant, they were all positive, with gradient consistent in direction and somewhat consistent in magnitude
with the corresponding eﬀect found in the HNSCC data
set. As reported in the Additional ﬁle 1, no bisulﬁte
conversion coeﬃcient was signiﬁcant, and all coeﬃcients
were of small magnitude (generally less than 1 percentage
point per standard deviation).
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method are consistent with known immunological perturbations associated with type II diabetes [9,10]. Complete
results are provided in the Additional ﬁle 1.
Additional analyses

We obtained the following unnormalized bias-corrected
estimates: 69.0% CD4+, 95% CI (54%, 84%), and 32.5%
CD8+, 95%CI (19%, 46%). This is consistent with known
proportions of these speciﬁc cell types among T
lymphocytes.
Results of simulations

Table 5 presents results for n1 = 200 with precise mixture weights (small within-status heterogeneity in distribution), while Table 6 presents results for n1 = 200
with noisy mixture weights (larger within-status heterogeneity). The tables show mean estimate, simulation standard deviation, median estimates for the three
types of proposed standard errors, and proportion of
p-values (obtained from z-scores constructed using the
double-bootstrap standard error) falling below α = 0.05
and α = 0.01. In all cases, the bias in estimation was
negligible. Both bootstrap procedures produced similar
standard error estimates, which were close to the simulation standard deviation but often quite diﬀerent from
the naive standard error estimate. Under null scenarios, the rejection probabilities were tolerably close to
their nominal values, and for alternatives, power could
be quite high, even with this modest design. Results
for the coeﬃcients of determination are provided in
the Additional ﬁle 1. Scenarios with n1 ∈ {100, 500} produced similar results, with simulation standard deviations
and power adjusted accordingly, but still having practical
utility.

Discussion
In this paper, we employ the concept of DMRs as markers
of immune cell identity using a high density methylation platform, and propose a set of analytical tools for
estimating the proportions of immune cells in unfractionated whole blood. The backbone of the approach is
the DNA methylation signature of each of the principal
immune components of whole blood (B cells, granulocytes, monocytes, NK cells, and T cells subsets). The
examples we have provided above serve to illustrate
that our proposed methodology produces parameter estimates consistent with the literature, thus validating its
utility.
Our proposed method resembles regression calibration,
where we consider a methylation signature to be a highdimensional multivariate surrogate for the distribution of
white blood cells. In turn, this distribution is of interest
for predicting or modeling disease states. As a surrogate,
the DNA methylation signature is assumed to be a highly
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correlated, yet imperfect, measure of leukocyte distribution, and thus ﬁts into the framework of measurement
error models, where the use of a noisy surrogate marker to
investigate an association with a disease outcome of interest results in biased estimates, unless internal or external
validation data can be obtained to “calibrate” the model
and correct the bias [12]. However, in this case, the problem is complicated by the extremely high dimension of the
surrogate. Measurement error problems are typically formulated as a set of relationships between z, the disease
outcome (e.g. case/control status), ω, the gold standard
(e.g. leukocyte distribution), and Y, the surrogate (e.g.
DNA methylation). Of interest is E(z|ω), which may be
diﬃcult to estimate due to the cost or logistical complications involved in obtaining ω in a large number
of samples. Typically, it is possible to collect suﬃcient
data for modeling E(z|Y), which provides information
about E(z|ω) through the (often imperfect) association
E(Y|ω), which is inferred from an external validation sample [12,34]. Unfortunately, the high-dimensional nature
of Y renders E(z|Y) diﬃcult to formulate. While multivariate methods of measurement error correction exist,
even in a high-dimensional context [35], they require an
explicit speciﬁcation of E(z|Y), requiring a large number of parameters even for a main eﬀects regression
model, and many more in order to account for interactions. This becomes unwieldy when each component of
Y contributes a small amount of information about z,
and both dimension-reduction strategies and constrained
regression strategies entail substantial loss of information
and may be extremely computationally intensive. Existing measurement error formulations [34,35] would have
required us to specify a logistic regression model for
case/control status, conditional on DNA methylation signature, a computationally diﬃcult task that would have
extreme vulnerability to model mis-speciﬁcation. On the
other hand, our method requires speciﬁcation of E(Y|z),
which is natural and straightforward. Note that in some
treatments of regression calibration, E(ω|Y) is used as a
surrogate for ω in regression models for z [12]; our treatment essentially assumes a linear form for E(Y|ω) and
eﬀectively obtains E(ω|Y) by projecting Y onto the column space of resulting matrix. We note that it is possible
using existing methods to qualitatively describe immune
response contributions to DNA methylation. This is typically done by conducting a pathway analysis along the
lines of one of the methods described in [36], the best
option of which is Gene Set Enrichment Analysis (GSEA)
[37]. For example, Teschendorﬀ et al. (2009) [22] use
GSEA to qualitatively motivate an immunological explanation. However, these methods do not directly quantify
the immunological contribution.
An important consideration in the measurement error
literature is that of transportability of model parameters
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Table 5 Simulation Results (Precise Mixtures, n1 = 200)
Strong Alternative I (θ = 0)
B Cell

Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

0.0

0.07

1.00

0.92

0.97

0.98

0.057

0.018

Granulocyte

8.0

8.02

0.73

0.39

0.73

0.73

1.000

1.000

Monocyte

0.0

0.01

0.48

0.43

0.47

0.47

0.055

0.013

0.0

−0.09

1.08

1.02

1.02

1.05

0.066

0.015

T Cell (cd4+)

−4.0

−4.06

0.81

0.80

0.78

0.81

0.999

0.989

T Cell (cd8+)

−2.0

−1.93

0.83

0.81

0.78

0.81

0.653

0.419

NK

Strong Alternative II (θ = 0)
Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

B Cell

0.0

0.00

0.97

0.92

0.97

0.99

0.048

0.016

Granulocyte

8.0

8.00

0.71

0.39

0.72

0.72

1.000

1.000

Monocyte

0.0

0.03

0.48

0.42

0.47

0.47

0.063

0.016

NK

0.0

0.03

1.04

1.02

1.01

1.05

0.052

0.014

T Cell (cd4+)

−6.0

−5.83

0.76

0.80

0.77

0.80

1.000

1.000

T Cell (cd8+)

0.0

−0.22

0.81

0.81

0.80

0.81

0.064

0.014

Mixed Alternative (θ = 0.5)
Truth
B Cell

0.0

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

−0.02

1.02

1.10

0.96

0.98

0.065

0.011

Granulocyte

4.0

3.99

0.75

0.47

0.73

0.73

1.000

0.995

Monocyte

0.0

0.02

0.49

0.51

0.47

0.47

0.060

0.015

NK

0.0

0.04

1.05

1.22

1.01

1.04

0.054

0.009

T Cell (cd4+)

−2.0

−2.07

0.82

0.96

0.79

0.83

0.695

0.471

T Cell (cd8+)

−1.0

−0.95

0.82

0.96

0.78

0.82

0.203

0.082

Mixed Null (θ = 1)
Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

B Cell

0.0

0.00

1.04

1.58

0.96

1.02

0.066

0.017

Granulocyte

0.0

0.03

0.73

0.67

0.74

0.74

0.055

0.014

Monocyte

0.0

−0.01

0.47

0.73

0.47

0.48

0.054

0.013

NK

0.0

−0.01

1.12

1.76

1.01

1.09

0.063

0.014

T Cell (cd4+)

0.0

0.01

0.87

1.38

0.80

0.90

0.054

0.013

T Cell (cd8+)

0.0

−0.02

0.88

1.39

0.79

0.89

0.057

0.015

Strong Null (θ = 0)
Truth
B Cell

0.0

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

−0.01

0.99

0.90

0.96

0.96

0.068

0.014

Granulocyte

0.0

0.03

0.72

0.38

0.74

0.73

0.052

0.013

Monocyte

0.0

−0.01

0.47

0.42

0.47

0.47

0.055

0.013
0.020

NK

0.0

−0.01

1.06

1.00

1.01

1.02

0.059

T Cell (cd4+)

0.0

0.00

0.81

0.78

0.80

0.82

0.054

0.013

T Cell (cd8+)

0.0

−0.01

0.81

0.79

0.79

0.80

0.054

0.015

Est = Men regression coeﬃcient estimate (× 100%); SD = SD regression coeﬃcient estimate (× 100%).
SE0 = Naive standard error (× 100%); SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
pow(α) = Pr{P2 < α}, where P2 is the p-value computed from SE2 .
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Table 6 Simulation Results (Noisy Mixtures, n1 = 200)
Strong Alternative I (θ = 0)
Truth
B Cell

0.0

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

−0.06

1.39

0.92

1.36

1.34

0.065

0.019

Granulocyte

8.0

7.87

2.02

0.39

2.00

1.99

0.974

0.897

Monocyte

0.0

0.05

1.03

0.42

1.04

1.02

0.049

0.012

0.0

−0.02

1.21

1.02

1.16

1.18

0.061

0.010

T Cell (cd4+)

−4.0

−4.00

1.23

0.79

1.21

1.22

0.903

0.739

T Cell (cd8+)

−2.0

−1.97

1.05

0.80

1.02

0.98

0.517

0.298

NK

Strong Alternative II (θ = 0)
Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

B Cell

0.0

−0.08

1.38

0.92

1.36

1.34

0.063

0.017

Granulocyte

8.0

7.90

2.03

0.39

1.99

1.98

0.973

0.905

Monocyte

0.0

0.10

1.07

0.42

1.04

1.02

0.054

0.019

NK

0.0

0.02

1.17

1.02

1.14

1.18

0.053

0.009

T Cell (cd4+)

−6.0

−5.70

1.19

0.80

1.13

1.16

0.999

0.986

T Cell (cd8+)

0.0

−0.23

1.08

0.81

1.10

1.04

0.066

0.015

Mixed Alternative (θ = 0.5)
Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

B Cell

0.0

0.05

1.42

1.10

1.34

1.34

0.066

0.016

Granulocyte

4.0

4.00

2.01

0.47

2.02

2.01

0.500

0.291

Monocyte

0.0

0.01

1.06

0.51

1.03

1.02

0.072

0.020

NK

0.0

−0.02

1.24

1.22

1.13

1.16

0.064

0.013

T Cell (cd4+)

−2.0

−2.11

1.30

0.95

1.26

1.28

0.391

0.191

T Cell (cd8+)

−1.0

−0.94

1.08

0.96

1.05

1.02

0.163

0.052

Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

0.0

0.06

1.41

1.59

1.36

1.37

0.062

0.016

Mixed Null (θ = 1)
B Cell
Granulocyte

0.0

0.04

2.08

0.67

2.06

2.05

0.056

0.008

Monocyte

0.0

−0.02

1.05

0.73

1.03

1.03

0.058

0.020

NK

0.0

0.01

1.26

1.76

1.14

1.22

0.066

0.011

T Cell (cd4+)

0.0

−0.01

1.42

1.38

1.31

1.36

0.067

0.016

T Cell (cd8+)

0.0

0.00

1.19

1.39

1.08

1.10

0.073

0.011

Strong Null (θ = 0)
Truth

Est

SD

SE0

SE1

SE2

pow(0.05)

pow(0.01)

B Cell

0.0

0.06

1.37

0.91

1.36

1.32

0.065

0.017

Granulocyte

0.0

0.03

2.07

0.38

2.06

2.05

0.055

0.009

Monocyte

0.0

−0.02

1.04

0.42

1.03

1.02

0.057

0.021

NK

0.0

0.01

1.19

1.01

1.14

1.16

0.053

0.018

T Cell (cd4+)

0.0

−0.04

1.38

0.79

1.31

1.31

0.069

0.015

T Cell (cd8+)

0.0

0.01

1.11

0.79

1.08

1.03

0.065

0.016

Est = Mean regression coeﬃcient estimate (× 100%); SD = SD regression coeﬃcient estimate (× 100%).
SE0 = Naive standard error (× 100%); SE1 = Single-bootstrap standard error (× 100%).
SE2 = Double-bootstrap standard error (× 100%).
pow(α) = Pr{P2 < α}, where P2 is the p-value computed from SE2 .
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[38]. In our setting, an important consideration is whether
the methylation proﬁles obtained from the puriﬁed blood
cells used to assemble S0 would be representative of the
white blood cells measured within S1 . Because of the biological assumptions inherent in the DMR literature and
underlying current understanding of hematopoeisis and
lineage commitment, this assumption is reasonable, provided our method is used to detect abnormal mixtures
of normal white blood cells. However, methylation abnormalities in the white blood cells themselves constitute a
form of non-cell mediated alteration (in the sense of the
term we have been using), and contribute to bias in our
methods, as described brieﬂy above and in detail in the
Additional ﬁle 1.
Note that our formulation respects the study design
(DNA methylation assay data collected after sampling
from phenotype groups). An alternative strategy outside the measurement error literature but within the
larger missing-data literature might have been the
use of an Expectation-Maximization (EM) algorithm
to integrate over the missing data ω [39]. However,
by design, the distribution of ω varied substantially
between the data sets S0 and S1 , severely complicating the approach; notably, an would be the introduction of feedback from S1 to S0 , contaminating the
gold-standard status of S0 . An alternative, might be
the use of an empirical Bayes procedure, reminiscent
of existing mixture-model approaches [40]. However,
diﬃculty in specifying the distribution of “remainder
terms” (denoted as ξ above) render this approach untenable, and in simulations (not presented), attempts to
impute ω among S1 samples using parameters obtained
from S0 samples resulted in extremely biased estimates
of ω.
The most signiﬁcant aspect of the current study is
our development of a method for inferring changes in
the distribution of white blood cell types between different human populations (e.g. cases and controls) using
DNA methylation signatures; an approach guided by an
external validation set consisting of methylation proﬁles
from puriﬁed white blood cell components. DNA methylation in peripheral blood is a potentially powerful new
biomarker for clinical and epidemiological investigation.
By example, numerous studies have now attempted to distinguish cancer cases from controls using whole peripheral blood assayed via DNA methylation arrays, including
ovarian [22], bladder [41], and pancreatic [42] cancers.
While these studies have demonstrated good to excellent discrimination of cases from controls, sound evidence
for a biological mechanism has been elusive. Presumably, disease associated alterations in blood methylation
have several etiological components driven by inherent
genetic, environmental and disease speciﬁc factors. Given
the known developmental associated diﬀerences in DNA
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methylation among speciﬁc blood cell types, changes in
the distributions of blood cell types alone could account
for disease associated DNA methylation. While numerous authors provide a qualitative discussion that includes
the possibility of immune-related DNA methylation differences (e.g.[22]), none to date has speciﬁcally quantiﬁed
the contribution from immune response. On the other
hand, the many diverse types of immune cells in blood
make this issue highly complex and problematic to tackle
using single cell type assays. Therefore, it is crucial to the
development of this new avenue of biomarker research to
delineate eﬀects due to the immune cell distribution itself
from other “non cell type” alterations in DNA methylation. We term the diﬀerences among human populations
attributed to cell distributions to be “immunologically
mediated”. Our solution to partition this component of
variation in methylation from other determinants are
multivariate analytic tools including regression coeﬃcients and associated inference, as well as coeﬃcients of
determination measures. Taken together these provide a
means for evaluating whether the observed DNA methylation diﬀerences are due to an immunologically mediated
response.
In our Additional ﬁle 1 we provide a detailed analysis of
potential sources of bias in our analysis. One obvious biological source of bias is age of the subjects contributing
cells for validation. At certain CpG loci, DNA methylation is known to change with age [43], especially in T
cells [44]. In the Additional ﬁle 1 we demonstrate that
any age-related associations with DNA methylation in our
top 100 CpGs were too weak to be detected with the current validation sample, and thus unlikely to bias the results
of our analyses (notably age coeﬃcients provided for the
HNSCC example). However, we remark that with larger
sample sizes, adjustments for age can be incorporated
with an appropriate additional term in the linear model (1)
for Y0h .
Similar methods based on mRNA have been employed
[13-15]. The statistical principles described in this article would apply, wholesale, to mRNA expression proﬁles,
but with two cautionary statements. The ﬁrst is mathematical: mRNA is typically analyzed on a logarithmic
scale, yet the assumptions of the proposed methodology
involve linearity on an arithmetic scale, since the mixing coeﬃcients are assumed to act linearly on absolute
numbers of nucleic acid molecules; thus, the proposed
methods would require analysis of untransformed ﬂuorescence intensities, whose skewed distributions would result
in numerical instabilities. The second is biological: there
is no necessarily linear relationship between cell number
and mRNA copies, since proteins may be translated as
a consequence of an initial burst of mRNA transcription
upon cellular development, after which signiﬁcant mRNA
degradation is possible. In contrast, one would expect
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the average beta value provided by Illumina bead-array
products (and similar quantities) to scale in proportion to
the actual fraction of methylated nucleic acids; in addition, an assumption of two DNA molecules per cell seems
biologically reasonable. In the Additional ﬁle 1 we provide an example of an application of our methods using
mRNA data.
Going forward there are two issues that require further
experimental and analytical reﬁnement. First, although
the current studies suggest group level comparisons
of blood cell DNA methylation can reveal important
immune alterations, it will be important to provide
methods for individual level immune cell proﬁling, since
clinical and detailed analytical epidemiologic applications
that examine individual risk factor information will be the
subject of future studies. As we have demonstrated above,
individual immune proﬁles are theoretically achievable
but will require extensive validation, with a wide array of
mixture combinations, before gaining widespread acceptance. Secondly, there is intense interest in minor immune
cell fractions and their role in disease, though the signal
strength of cell types comprising < 5% of the total white
cell compartment may be diﬃcult to quantitate. Examples of such cell types include the regulatory T-cell or NK
cell fractions, which are implicated in autoimmune and
malignant diseases. Optimization of platforms for technical sensitivity to minor subtypes combined with statistical optimization of signature recognition are needed to
enhance the approach for testing highly targeted immune
hypotheses.

Conclusions
The method we present here has potentially far reaching
implications for rapid, simple and complete assessment
of the composition of human white blood cell populations, i.e. the immune proﬁle. Currently, assessment of
the cellular composition of peripheral blood cannot be
accomplished without the use of freshly drawn venous
blood that is immediately prepared in a specially equipped
laboratory. A complete assessment of the entire immune
proﬁle requires extensive ﬂow cytometric measurements
based on protein epitopes on leukocyte membranes that
distinguishes subtypes of immune cells that are either too
rare or too similar in appearance to be distinguished using
simple microscopic approaches. In particular, ﬂow cytometry is limited by the following: (i) cells must be separated,
requiring large volumes of fresh cells; (ii) detection can
be accomplished only by the ﬂuorescent antibody tags
available, which require expensive technology to read; (iii)
the outer cell membrane must be intact, mandating limited utility in many instances (particularly in research).
In contrast, our method requires the application of these
labor-intensive or expensive steps only in the construction of the validation set S0 , which need only be developed
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once. Once S0 is available, subsequent interrogation is
based on the chemically stable CpG methylation of DNA;
thus our method obviates the need for fresh blood and
the preservation of labile protein epitopes. It is also able
to simultaneously assess all of the individual components
of the peripheral blood using a highly multiplexed molecular platform and is thus very straightforward logistically.
Furthermore, the statistical methodology presented here
can be implemented easily with the instrumental output
of the methylation arrays, which simpliﬁes the interpretation of the immune proﬁle data from the operators point
of view. This method can be immediately deployed in
a research framework to cost eﬀectively assess human
immune proﬁles (in fresh or archival samples), exploring
their potential as biomarkers, and addressing key questions regarding disease pathogenesis. Furthermore, our
approach is readily suited for rapid translation to a broad
base of clinical applications such as disease monitoring,
diagnosis, prognosis, and response to therapy.
Our approach makes research on biobanked specimens
possible, now making a vast array of prospective studies
that could not otherwise be done, possible. Software and
sample data are provided in Additional ﬁle 2.

Additional ﬁles
Additional ﬁle 1: Houseman-WBC-BMCBioinformaticsSupplement.pdf. Additional theoretical details, simulation descriptions
and results, and additional ﬁgures and result tables [43-52].
Additional ﬁle 2: Houseman-WBC-BMCBioinformatics-Software-v2.
Sample R software (compressed).
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